Bloomberg Daybreak Europe, anchored live from London, tracks breaking news in Europe and around the world. The FTC filed a lawsuit in March 2021 to stop Illumina's deal to buy its former subsidiary Grail, arguing it would slow innovation for tests designed to detect multiple kinds of cancer. (Bloomberg) -- Illumina Inc.'s $7 billion takeover of cancer-test provider Grail Inc. was vetoed by the European Union amid concerns that the deal would have hampered competition. Meta Plans to Begin Large-Scale Layoffs This Week, How to Escape Your Packed Schedule and Take a Rest From Work, Russia Presses Evacuation of Kherson as Ukrainian Offensive Looms, Opinion: Democrats Develop Elon Musk Derangement Syndrome, Opinion: Donald Trump Rallies for . retaliate against it for registering antitrust concerns regarding Illumina's acquisition of cancer early detection firm Grail . and Rep. Mondaire Jones (D-N.Y.), introduced a bill Wednesday that would give federal antitrust enforcers greater power to block and break up mergers . The Illumina/Grail merger, which had already attracted a lot of notice in the US and was further brought to the attention of the Commission through a complaint received in December 2020, appeared to be the perfect candidate. Cut Taxes and Spending, Watch: Griner to Serve Nine-Year Sentence After Judge Denies Appeal, Watch: Climate Protesters Throw Mashed Potatoes on $110 Million Monet Painting, Mortgages, Cars and Credit Cards: How Interest-Rate Hikes Are Hitting Americans' Wallets, Putinisms: Vladimir Putins Top Six One Liners. Sie knnen Ihre Einstellungen jederzeit ndern. Illumina said it would challenge the EU veto outlined in a document of more than 600 pages. The Financial Times reported. 2 min read By Deena Beasley (Reuters) -Cancer detection test maker Grail, acquired by Illumina Inc last year despite ongoing antitrust challenges, on Tuesday said. Illumina sells next-generation gene sequencing (NGS) equipment and consumables, while Grail is developing a multi-cancer early detection test that uses Illumina's NGS platform. Illumina shares closed down 2.3% on Friday. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Following a four-week trial before the special administrative court of the US Federal Trade Commission (FTC), Latham antitrust litigators persuaded Administrative Law Judge D. Michael Chappell to rule in favor of Latham client GRAIL and its acquirer, Illumina - marking the first time the FTC's administrative law judge has ever ruled against the FTC in a merger case. life sciences. . The Federal. (Reporting by Foo Yun Chee; editing by Philip Blenkinsop and David Evans), Looking for winning Powerball numbers in record $1.9B jackpot? In short, Illumina could refuse to sell, or sell only at higher prices or after significant delay, the DNA sequencing instruments and consumables that, the FTC asserts, have no readily available substitutes. Written by Illumina sues Guardant CEOs over trade secrets, sparking counterblast against 'retaliatory' lawsuit By Nick Paul Taylor March 18, 2022 Guardant called the lawsuit "frivolous and retaliatory" and framed it as a response to its concerns about the Illumina-Grail merger. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. About Galleri The earlier that cancer is detected, the higher the chance of successful outcomes But the judge "rejected the FTC's position that the deal would adversely affect competition in a putative market for multi-cancer early detection tests," Illumina said on Thursday. . NEW YORK - Illumina on Thursday filed a lawsuit against Guardant Health with the US District Court for the District of Delaware for correction of inventorship, trade secret misappropriation, and breach of contract. Illumina closed the deal in August 2021 but said it would hold Grail as a separate company with regard to the EU review. First, the Complaint alleges that Illumina will have the ability to foreclose or raise the costs of Grail's MCED rivals in several ways. Illumina Inc. won a US Federal Trade Commission lawsuit seeking to unwind its $7 billion acquisition of cancer-startup Grail Inc. after an administrative judge ruled the tie-up didn't violate. You may change your billing preferences at any time in the Customer Center or call "Our in depth investigation confirmed our initial concerns. We analyzed Grail's patent portfolio and found that the company's most widely deployed patent families are valuable in the patent market. Copy and paste multiple symbols separated by spaces. Dies geschieht in Ihren Datenschutzeinstellungen. A Guide to Climate Overshoot, NYC Kids Are Still Leaving Public Schools in Pandemic-Fueled Exodus, Why Georgia Is Keeping Such a Close Watch onAtlantas Elections, How a Death Star-Shaped TreehouseLanded in Austins Favorite Park, Kim Kardashian Poised to Beat Investor Suit Over Crypto Hype, Formula One Sponsorships From Crypto Firms Dwindle With Downturn, Ethereum Insiders to Get Fee Cuts That Others Wont in Upgrade. U.S. antitrust authorities sued to. In a landmark decision, the European Commission (Commission) has prohibited Illumina's $7.1 billion completed acquisition of GRAIL, following an Article 22 EU Merger Regulation (EUMR) referral. Illumina, which has challenged the Commission's veto, will be required to provide funds for Grail to develop cancer detection tests it has in the pipeline. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Donald Trump, Opinion: The Cure? The FTC filed a lawsuit in March 2021 to stop Illumina's deal to buy its former subsidiary Grail, arguing it would slow innovation for tests designed to detect multiple kinds of cancer. . The EU watchdog said Illumina offered to give a licence for its NGS patents to some NGS suppliers, with provisions in agreements valid until 2033. Customer Service. (Reporting by David Shepardson in Washington Editing by Jonathan Oatis and Matthew Lewis), ((Chris.Sanders@thomsonreuters.com; +1 202-558-8254; Reuters Messaging: chris.sanders.reuters.com@reuters.net)). "Our investigation showed that the proposed remedies would not have been effective in practice, and they would be very easy to circumvent. Those requests, which are part of Illumina's defense strategy in the FTC suit challenging its $8 billion reacquisition of Grail, contain highly sensitive trade secrets, according to Caris. Illumina closed the deal in August 2021 but said it would hold Grail as a separate company with regard to the EU review. Further, Illumina stated that while it prepares for the expected divestment order from the European Commission, it will begin reviewing strategic alternatives for Grail. Vestager criticised the company, saying it has created a troublesome situation. Ron DeSantis, a national Republican star, faces off against Democrat Charlie Crist in Florida's gubernatorial election. The FTC said it had filed an administrative complaint and authorized a federal court lawsuit to block the deal, which is valued at $7.1 billion. The vote to sue was unanimous. The Commission had taken jurisdiction to review the transaction on April 19, 2021, [1] and started an in-depth investigation on July 22, 2021, with a final decision expected by . Monitor your investments 24 hours a day, around the clock from around the globe. 23. Customer Service. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ:ILMN) currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October 2021. Oct 14, 2022 02:07pm. 3/31/2021 The FTC (Federal Trade Commission) recently filed an admission complaint along with a federal court lawsuit to block Illumina 's ILMN $7.1 billion proposed acquisition of cancer. Read the full article Moving In Together Doesnt Match the Financial Benefits of Marriage, but Why? "Illumina's lawsuit comes shortly after Guardant cooperated with the (Federal Trade Commission) in its antitrust investigation of the proposed Illumina-Grail transaction, and just months after two . Do Not Sell My Personal Information (CA Residents Only). The FTC filed two lawsuits related to the Illumina-Grail plan earlier this year. In. The FTC has said it will appeal. 2 Faces Challenge to Make Chinas Economy Hum Again, Korea Urges More ESG Focus on Women to Address Fertility Crisis, Adidas, Nike Must Pick Up the Pieces After Antisemitism RuinsDeals, COP27 Latest: Japan Stalls Once Again on Carbon-Tax Reforms, What Happens After Warming Hits1.5C? In the meantime, Illumina closed the transaction in August 2021 before the EC had completed its investigation. David Shepardson for FTC Appeals Judge's Dismissal of Suit Against Illumina Deal Company's $7.1 billion acquisition of a cancer-test developer will now be considered by the five-member commission Illumina could ask. The agency last year sued in its in-house court to block the merger, which it alleged would harm innovation for early-stage cancer detection tests. Illumina Inc. won a US Federal Trade Commission lawsuit seeking to unwind its $7 billion acquisition of cancer-startup Grail Inc. after an administrative judge ruled the tie-up didnt violate antitrust law, the company said. Anchored by Anna Edwards and Mark Cudmore, Bloomberg Markets Europe is a fast-paced hour of news and analysis, building towards the drama and excitement of the start of the cash trade across the continent. James Parkinson. The FTC alleges a . Illumina completed the deal in August last year ahead of EU regulatory approval, resulting in an EU order to keep Grail separate and appoint independent managers to run the company until the investigation's conclusion. TechCrunch - Natasha Lomas 10h. . Will the No. Illumina has a rather convoluted history in the liquid biopsy space. The Federal Trade Commission's ongoing feud with Illumina over its $7.1 billion bid to acquire cancer diagnostic firm Grail has taken another twist with the FTC asking a San Diego judge to . . Now, Illumina has Grail back, unless . Mergers and Acquisitions Europe Cross-Jurisdiction The US Federal Trade Commission's lawsuit to block Illumina's acquisition of Grail contains some ominous portents for Lockheed's proposed combination with Aerojet Rocketdyne. Reuters, the news and media division of Thomson Reuters, is the worlds largest international multimedia news provider reaching more than one billion people every day. The deal would mean Illumina would have no incentive to provide the DNA sequencing to Grail's rivals, or would have an incentive to try to raise their costs, the FTC had argued. I Love Wine transports you to the best winemaking regions of the world, Hong Kong Foreign Worker Arrivals Plummet as Covid Rules Drag On, Covid Surge Tempers Hopes IPhone City Lockdown Will Lift Soon, Kishida to Approve $198 Billion Extra Budget for Stimulus, China Downgrades Priority of Economy for Future Legislation, UK Shop Sales Slow as Consumers Shift Spending Toward Essentials. . The FTC said its reviewing the decision and evaluating next steps. Gene sequencing company Illumina ( NASDAQ: ILMN) has won a lawsuit filed by the Federal Trade Commission over its 2021 acquisition of cancer test developer GRAIL, The Wall Street Journal. ]. During that time Illumina made it clear it wanted to bring Grail, the company it launched in 2016, back into the fold. Key Points. Under FTC rules, the decision is subject to review by the full Federal Trade Commission. Lawsuit is Seen as an Attempt to Stifle Competition and Retaliate Against Guardant Health for Registering Concerns About the Antitrust Implications of Illumina's Acquisition of Grail March 17 . This is the first instance where the Commission has blocked a transaction where the . FTC alleged deal would harm innovation in cancer detection, European regulators still reviewing deal, which closed in 2021, Twitter Now Asks Some Fired Workers to Please Come Back, Elon Musk Walks Back on Twitter Job Cuts, Blue Checks in Second Week, Billions in Capital Calls Threaten to Wreak Havoc on Global Stocks, Bonds, Twitter Fires More Than 90% of India Staff, Leaving Just a Dozen, Small Businesses Find a Loophole in the New Tax Law: Zelle. It would be four years later that Grail would make an attempt to go public and Illumina would swoop back in and try to acquire it. Increasing competition has been a mandate of the Biden administration, and the director of the FTC's Bureau of Competition, Holly Vedova, had said on Thursday the agency was considering challenging the judge's ruling. The ruling has not yet been made public. Alcon, J&J Vision settle for $75M in contact lens price-fixing case. The deal would have given Illumina access to Grail's flagship Galleri blood test used to diagnose cancers at early stages when the disease is easier to treat. Durch Klicken auf Alle akzeptieren erklren Sie sich damit einverstanden, dass Yahoo und seine Partner Ihre personenbezogenen Daten verarbeiten und Technologien wie Cookies nutzen, um personalisierte Anzeigen und Inhalte zu zeigen, zur Messung von Anzeigen und Inhalten, um mehr ber die Zielgruppe zu erfahren sowie fr die Entwicklung von Produkten. This led the EC to adopt, in October 2021, hold-separate and interim measures . The FTC filed a lawsuit in March 2021 to stop Illumina's $7.1. European regulators vetoed Illumina's $7.1 billion acquisition of Grail on Tuesday, forcing Illumina to divest the biotech less than one week after a US judge ruled against an FTC challenge, Reuters reported.. The. One suspects the litigation will continue on this side of the Atlantic too. The Federal Trade Commission has sought to block Illumina's planned $7.1bn acquisition of Grail, the cancer screening start-up backed by Jeff Bezos and Bill Gates, citing concerns . In particular, Illumina proposed to openly license to NGS suppliers some of its NGS patents and to stop lawsuits in . A former Illumina subsidiary, Grail has developed a blood test for 50 types of cancers. The case was seen as a test of a more aggressive policy by the agency. Illumina is fighting antitrust reviews on both sides of the Atlantic in its bid to re-purchase Grail, which it launched in 2016 but subsequently spun off. The last week has seen crucial developments at the European Commission (EC) and U.S. Federal Trade Commission (FTC) regarding the antitrust review of the $7.1 billion proposed acquisition by Illumina (the leading supplier of next generation screeners (NGS)) of cancer screening startup GRAIL. The. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. The European Commission, which acts as the competition enforcer in the 27-country bloc, said on Tuesday that Illumina's remedies did not adequately address its concerns, confirming a Reuters story in July. Illumina acquired Grail for US$ 8 billion while struggling to get regulatory clearance in the U.S. and EU; Illumina may be required to undo the acquisition if it loses the case. The target, Grail, was formed by Illumina in 2015 and spun off in 2016, with Illumina retaining 20% equity interest (since reduced to about 14%). Illumina offered a licence to NGS suppliers to some of Illumina's NGS patents, and a commitment to stop patent lawsuits in the U.S. and Europe against the NGS supplier BGI Genomics (China) for three years to reduce IP-related barriers to entry. The European Commission's most recent ruling adds another layer of complexity to a saga that began in September of 2020. Microsoft's $68.7 billion all-cash deal to bag gaming giant Activision Blizzard faces closer antitrust scrutiny in the U.K. where the country's market watchdog has just announced it will move to an in-depth investigation unless the pair submit suitable proposals to address its concerns in the . When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. (FTC) sought to challenge the acquisition in 2021, arguing that Illumina's purchase of GRAIL, which it had previously spun off in 2016, would hurt innovation in the US market for early detection tests for multiple cancers. Separately, Illumina faces an EU fine of as much as 10% of its annual global turnover for jumping the gun and has set aside $453 million for this. Illumina said it will hold Grail as a separate company . Fr nhere Informationen zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklrung und Cookie-Richtlinie. Illumina closed the deal in August 2021 but said it would hold Grail as a separate company with regard to the EU review. The FTC has said Illumina is the dominant provider of DNA sequencing for multi-cancer early detection tests, which Grail uses to make a blood test to detect cancers. Second, the Illumina/Grail prohibition decision will further concentrate the minds of parties . (if applicable) for The Wall Street Journal. Klicken Sie auf Einstellungen verwalten, um weitere Informationen zu erhalten und Ihre Einstellungen zu verwalten. "To prepare for the anticipated divestment order from the European Commission in the coming months, the company will begin reviewing strategic alternatives for Grail in the event the divestiture is not stayed pending Illumina's appeal," it said in a statement. Trial expected to run until at least early October (Reuters) - Lawyers for Illumina Inc are set to defend the life sciences company's $7.1 billion acquisition of Grail Inc at the U.S. Federal. Sign In. The move means the case will now be considered by the five-member commission, which is composed of three Democratic members and two Republicans. On August 18, 2021, U.S. gene-sequencing company Illumina publicly announced it had acquired Grail, a start-up that has developed multi-cancer early detection tests. Co-founder and managing director of the National Law Review, one of the highest volume business law websites in the U.S. A certified Women Owned Business. September 12, 2022. The FTC staff filed a notice Friday appealing the decision. In September 2020, Illumina agreed to acquire Grail, a U.S.-based developer of blood tests for multiple early stage cancers, for US$7.1 billion. Illumina scored a victory last week when a U.S. administrative judge backed its challenge against a lawsuit by the Federal Trade Commission (FTC) against the deal. Already a member? It contends the lawsuit is payback for Guardant. WASHINGTON, Sept 2 (Reuters) - The Federal Trade Commission said it would appeal a decision issued on Thursday by the agency's chief administrative judge in favor of Illumina Inc's ILMN.O $7.1 billion acquisition of cancer detection test maker Grail Inc. Judge D. Michael Chappell ruled the acquisition will not hurt competition, in a blow to the agency, which was challenging the deal. Liquid biopsy pioneer Grail is kind of like a boomerang for Illumina ( ILMN 5.87%). Reuters reported in July that Illumina's acquisition of Grail will likely be blocked by EU antitrust regulators because of concerns about concessions offered by the U.S. life sciences firm. The gene sequencing giant spun out Grail, a company focused on early cancer detection in 2016. NEW YORK - The European Union's General Court ruled on Wednesday that the European Commission's investigation into Illumina's purchase of Grail can continue. SAN DIEGO & MENLO PARK, Calif.- (BUSINESS WIRE)- Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. The FTC filed a lawsuit in March 2021 to stop Illumina's $7.1. Most merger lawsuits involve challenges . Illumina has finalised its acquisition of cancer screening company Grail, despite both antitrust concerns from the EU and a pending legal challenge by the US Federal Trade Commission (FTC).. Grail, backed by Jeff Bezos and Bill Gates, is a cancer diagnostics firm originally spun-out of Illumina in 2016. The first was to argue against the merger on the basis of competition because of Grail's market advantages. Failure to comply would trigger. Reuters->. Illumina, a gene-sequencing powerhouse in San Diego, prevailed over the . The deals, which are in significantly different industries, nonetheless share important structural similarities. You'll have to wait, 911 call made from Apple Watch of Washington woman buried alive released, Jackson, in dissent, issues first Supreme Court opinion, Sylvester Stallone turned down $34 million Rambo paycheck, talks biggest regrets: 'I wasted a lot of time', Rapper Hurricane G dies at 52 after battle with lung cancer, More than 160 Lakota Artifacts Repatriated, Bands, marchers, sports cars, military vehicles highlight Clematis Street salute to veterans, Incumbent Gov. in major antitrust case. BRUSSELS (Reuters) -U.S. life sciences firm Illumina will have to divest biotechnology company Grail after an EU veto of the $7.1 billion acquisition over concerns it would hurt competition and stifle innovation. However, Illumina's M&A plans hit a snag when the FTC filed a lawsuit to block the deal. The course of the authorities' investigation of this transaction brings important lessons for parties . Illumina wins FTC GRAIL lawsuit in $7.1 billion deal . Daten ber Ihr Gert und Ihre Internetverbindung, wie Ihre IP-Adresse, Browsing- und Suchaktivitten bei der Nutzung von Yahoo Websites und -Apps. The FTC in May 2021 dismissed its federal court lawsuit, preferring to go ahead with the administrative proceeding, arguing the federal court case was no longer needed since the European Commission was investigating. Redwood City-based Guardant Health, a publicly traded cancer diagnostics company with 1,373 full-time employees, denied Illumina's accusations. We are delighted that you'd like to resume your subscription. It showed that Illumina holding a dominant position in NGS systems would have both the ability and the incentive to obstruct rivals," EU antitrust chief Margrethe Vestager told a news conference, referring to next generation sequencing (NGS). By Deena Beasley Sept 20 (Reuters) - Cancer detection test maker Grail, acquired by Illumina Inc last year despite ongoing antitrust challenges, on Tuesday said it would expand use of its. This is the second time that the European Commission has halted its scrutiny. The remedies offered, they were so complex that it would be hard for market participants and for the Commission to monitor and to enforce immunise compliance," she said. Type a symbol or company name. You will be charged Illumina defeats F.T.C. The European Commission (EC) stated the merger would stifle innovation and competition in the Next-generation sequencing (NGS) market, and that Illumina's recent attempts to address . They were down 0.4% after hours. Rakutens Bonds Tumble on Concerns Over Earnings in Japan, Nintendo Cuts Switch Sales Forecast After Chips Shortage, Twitter Engineer Files Retaliation Complaint Over Job Cuts, Jeep Maker Stellantis Pauses Twitter Ads, Joining GM and VW, Imran Khan Rejects Pakistan Police Report Into Shooting, Chinese Warplane Incursions Near Taiwan Rise to Three-Month High, CEO of Australias Top Pension Terrified of Global Cash Grabs, Billionaire Ken Griffin Praises New Florida Home: Its Not the Low Taxes, Swedish Property Startup Bodil Gets Funding as Home Prices Seen Falling, DeGrom, Correa, Bogaerts, Rodn Turn Down Options, Go Free, Gaming Out Market Reactions to the US Midterm Elections, Liverpool Going on Sale Highlights Soccers Financial Fickleness, A Mild Winter Brings Banks in From the Cold, Twitters Big Debt Bills Add Urgency to Musks Turnaround Plans, Xis New No. Create your Watchlist to save your favorite quotes on Nasdaq.com. Illumina. Illumina's acquisition of GRAIL seems to have fallen through which means they wasted a great deal of resources as a result of consistently bad decision-making. BRUSSELS, Sept 6 (Reuters) - U.S. life sciences firm Illumina (ILMN.O) will have to divest biotechnology company Grail (GRAL.O) after an EU veto of the $7.1 billion acquisition over concerns it. June 3, 2021 By Sean Whooley A U.S. judge has ruled in favor of an FTC petition to drop its case against the proposed merger between Illumina (NSDQ:ILMN) and Grail. Kitco News BRUSSELS, Feb 4 (Reuters) - EU antitrust regulators have temporarily paused their investigation into U.S. life sciences company Illumina (ILMN.O) bid for $8 billion cash-and-stock takeover of Grail (GRAL.O) while waiting for the companies to provide details. Whether or not the deal is ultimately approved, Grail and its peers are likely to be a game-changer for . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2022, Nasdaq, Inc. All Rights Reserved. Bloomberg A. Illumina is a U.S. biotech company and a leader in next-generation sequencing systems (NGS). CNA. Type a symbol or company name. WASHINGTONAntitrust enforcers at the Federal Trade Commission have appealed an administrative-law judges decision to dismiss a lawsuit challenging Illumina Inc.s $7.1 billion acquisition of cancer-test developer Grail Inc. Overnight on Wall Street is morning in Europe. Illumina formed Grail to build on that research, spinning it out as an independent company in 2016. You will be notified in advance of any changes in rate or terms. Caris Life Sciences Facing FTC Lawsuit After Resisting Subpoena in Illumina, Grail Antitrust Case Dec 01, 2021 | Andrew P. Han Save for later NEW YORK - Caris Life Sciences has been caught in the crossfire between the US Federal Trade Commission and Illumina, as they clash over Illumina's decision to acquire Grail. FTC Chairwoman Lina Khan, who leads the commission and has taken a stricter view of antitrust violations, would participate in the review. Illumina is already in talks with the Commission to divest Grail, people familiar with the matter told Reuters on Monday. These symbols will be available throughout the site during your session. 2 min read By Foo Yun Chee BRUSSELS (Reuters) -U.S. life sciences firm Illumina will have to divest biotechnology company Grail after an EU veto of the $7.1 billion. In an order issued Wednesday, the court dismissed a lawsuit filed by Illumina in April 2021, which challenged the investigation on jurisdictional grounds. FTC's . Grail, headquartered in Menlo Park, California, was launched by Illumina to develop applications of Illumina's NGS systems to create blood tests that would detect cancers at early stagesbefore . It has been developing liquid biopsy tests that examine blood samples for genetic signs of . Get 15% off AE promo code with text alerts, Kohl's coupon - 30% off sitewide for Rewards members, Tyson Foods CFO Arrested After Authorities Say He Fell Asleep in Wrong House. $ + tax The giant in gene-sequencing systems spun off Grail several years ago. Illumina announced its acquisition of the cancer-detection . Grail was originally formed in 2015 as a subsidiary of Illumina, but Illumina spun it off in 2017 so that . U.S. antitrust enforcers sued to block genetic-sequencing giant Illumina Inc. 's $7 billion acquisition of Grail Inc., a cancer-test startup backed by Jeff Bezos and Bill Gates. Markets never sleep, and neither does Bloomberg News. Vestager said she would issue a separate decision in due course ordering Illumina to dissolve the deal and restore Grail's independence. The case has added significance because Illumina's proposed acquisition of Grail Inc. is a vertical merger of companies that don't compete head-to-head. The Federal Trade Commission filed an administrative complaint and authorized a federal court lawsuit to block Illumina's $7.1 billion proposed acquisition of Graila maker of a non-invasive, early detection liquid biopsy test that can screen for multiple types of cancer in asymptomatic patients at very early stages using DNA sequencing. Much to management's chagrin, the giant of gene sequencing hardware, Illumina ( ILMN 7.73%), recently got a sharp rebuke in the form of an administrative complaint and federal lawsuit from the . Jurisdictional conflicts The prohibition of the Illumina/GRAIL merger in the EU comes less than a week after Illumina won the lawsuit brought by the US Federal Trade Commission to prevent the merger. For more information, please visit www.grail.com. 2 Movie Theater Chain Find aHappy Ending? The Federal Trade Commission filed an administrative complaint and authorized a federal court lawsuit to block Illumina's $7.1 billion proposed acquisition of Graila maker of a non-invasive, early detection liquid biopsy test that can screen for multiple types of cancer in asymptomatic patients at very early stages using DNA sequencing. You may cancel your subscription at anytime by calling It also offered a three-year patent truce with Chinese rival BGI Genomics.